Status:
COMPLETED
A Study Using the LMC Diabetes Registry to Learn More About Chronic Kidney Disease (CKD) in Canadian Patients With Type 2 Diabetes (T2D)
Lead Sponsor:
Bayer
Conditions:
Chronic Kidney Disease in Type 2 Diabetes
Eligibility:
All Genders
Brief Summary
In people with type 2 diabetes (T2D), the body does not make enough of a hormone called insulin or does not use insulin well. This results in high blood sugar levels. People with T2D are at a higher ...
Eligibility Criteria
Inclusion
- Clinical diagnosis of T2D as captured in the LMC EMR system
- Assessed by an LMC endocrinologist between January 1, 2019 and December 31, 2019
- Followed by an LMC endocrinologist for ≥ 6 months prior to inclusion in the cohort
- Informed consent to use patient medical record data for research purposes was provided
- Among patients who meet the inclusion criteria, estimated glomerular filtration rate (eGFR) ≤ 60 ml/min/1.73 m\^2 and/or urine albumin-to-creatinine ratio (uACR) ≥ 2 mg/mmol will be used to identify the cohort of patients with T2D and CKD
Exclusion
- \- Any patients with documented non-diabetic etiology for renal disease will be excluded from the numerator (number of patients with CKD and T2D) when determining the primary endpoint
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 23 2020
Estimated Enrollment :
14873 Patients enrolled
Trial Details
Trial ID
NCT04445181
Start Date
July 1 2020
End Date
November 23 2020
Last Update
October 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
A Database
A Database, Canada